A Study to Compare TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Public ClinicalTrials.gov record NCT06747351. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Single-Arm, Multiple-Dose, Pharmacokinetic Comparability Trial Between TAK-881 and HYQVIA in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The main aim of this study is to evaluate the pharmacokinetic (PK) comparability between TAK-881 and HYQVIA subcutaneous (SC) administration for maintenance therapy of CIDP. The participants who are already receiving intravenous immunoglobulin G (IGIV), conventional subcutaneous intravenous immunoglobulin G (cIGSC), or HYQVIA will be treated with the same dose equivalent as their prior IG treatment with HYQVIA for 20 weeks followed by TAK-881 for 24 weeks. Participants will need to visit the clinic every 3 or 4 weeks until they enter the extension phase. In the extension phase, home infusions are allowed, and visits will occur between every 12 weeks and 24 weeks.
Study identification
- NCT ID
- NCT06747351
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 59 participants
Conditions and interventions
Interventions
- TAK-881 Biological
- HYQVIA Biological
- SC Investigational Needle Sets Device
Biological · Device
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 5, 2025
- Primary completion
- Jun 24, 2028
- Completion
- Jun 24, 2028
- Last update posted
- Jan 19, 2026
2025 – 2028
United States locations
- U.S. sites
- 16
- U.S. states
- 12
- U.S. cities
- 16
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| HonorHealth Neurology | Scottsdale | Arizona | 85251 | Recruiting |
| Stanford Neuroscience Health Center | Palo Alto | California | 94304 | Not yet recruiting |
| Yale University School of Medicine | New Haven | Connecticut | 06510 | Not yet recruiting |
| Neurology Associates | Maitland | Florida | 32751 | Recruiting |
| Knight Neurology | Rockledge | Florida | 32955 | Recruiting |
| The Washington University | St Louis | Missouri | 63130 | Not yet recruiting |
| NYU Langone Health | New York | New York | 10016 | Recruiting |
| University of North Carolina (UNC) | Chapel Hill | North Carolina | 27599 | Recruiting |
| Duke University Hospital | Durham | North Carolina | 27710 | Recruiting |
| Raleigh Neurology Associates | Raleigh | North Carolina | 27607 | Recruiting |
| Atrium Health Wake Forest Baptist | Winston-Salem | North Carolina | 27157 | Recruiting |
| Cleveland Clinic | Cleveland | Ohio | 44195 | Not yet recruiting |
| Oregon Health & Science University (OHSU) - Nephrology and Hypertension Clinic - Marquam Hill | Portland | Oregon | 97239 | Not yet recruiting |
| Neurology Rare Disease Center | Denton | Texas | 76208 | Recruiting |
| The University of Vermont Medical Center | Burlington | Vermont | 05401 | Not yet recruiting |
| BCN Research, LLC | Greenfield | Wisconsin | 53228 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 36 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06747351, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 19, 2026 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06747351 live on ClinicalTrials.gov.